RT info:eu-repo/semantics/article
T1 Real-life outcomes in biotypes of psychotic disorders based on neurocognitive performance
A1 Molina, Vicente
A1 Fernández-Linsenbarth, Inés
A1 Queipo-de-Llano, María
A1 Jiménez-Aparicio, María Teresa
A1 Vallecillo-Adame, Carmen
A1 Aremy-Gonzaga, Abril
A1 de-Andrés-Lobo, Celia
A1 Recio-Barbero, María
A1 Díez, Álvaro
A1 Beño-Ruiz-de-la-Sierra, Rosa M.
A1 Martín-Gómez, Carmen
A1 Sanz-Fuentenebro, Javier
AB Aiming at discerning potential biotypes within the psychotic syndrome, we have recently reported the possible existence of two clusters or biotypes across schizophrenia and bipolar disorder characterized by their cognitive performance using the Brief Assessment of Cognition in Schizophrenia (BACS) instrument and validated with independent biological and clinical indexes (Fernández-Linsenbarth et al. in Schizophr Res 229:102–111, 2021). In this previous work, the group with larger cognitive deficits (N = 93, including 69 chronic schizophrenia, 17 first episodes (FE) of schizophrenia and 7 bipolar disorder patients) showed smaller thalamus and hippocampus volume and hyper-synchronic electroencephalogram than the group with milder deficits (N = 105, including 58 chronic schizophrenia, 25 FE and 22 bipolar disorder patients). We predicted that if these biotypes indeed corresponded to different cognitive and biological substrates, their adaptation to real life would be different. To this end, in the present work we have followed up the patients’ population included in that work at 1st and 3rd years after the date of inclusion in the 2021 study and we report on the statistical comparisons of each clinical and real-life outcomes between them. The first cluster, with larger cognitive deficits and more severe biological alterations, showed during that period a decreased capacity for job tenure (1st and 3rd years), more admissions to a psychiatric ward (1st year) and a higher likelihood for quitting psychiatric follow-up (3rd year). Patients in the second cluster, with moderate cognitive deficits, were less compliant with prescribed treatment at the 3rd year. The differences in real-life outcomes may give additional external validity to that yielded by biological measurements to the described biotypes based on neurocognition.
PB Springer
SN 0940-1334
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/66439
UL https://uvadoc.uva.es/handle/10324/66439
LA spa
NO European Archives of Psychiatry and Clinical Neuroscience 273(6):1379-1386
DS UVaDOC
RD 12-sep-2024